Bile Duct Cancer Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working

The formation of malignant (cancer) cells in the bile ducts is an uncommon condition known as bile duct cancer.

The liver, gallbladder, and small intestine are connected by a network of tubes known as ducts. This system starts in the liver, where a network of tiny ducts collects bile (a fluid made by the liver to break down fats during digestion). The right and left hepatic ducts, which lead out of the liver, are formed by the tiny ducts coming together. Outside the liver, the two ducts merge to form the common hepatic duct.

Cholangiocarcinoma is another name for bile duct cancer. 

 DelveInsight’s “Bile Duct Cancer – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bile Duct Cancer, historical and forecasted epidemiology as well as the Bile Duct Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Bile Duct Cancer Market Report: 

  • Bile Duct Cancer is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The major function of the bile duct is to move a fluid called bile from the liver and gallbladder to the small intestine, where it helps digest the fats in food. The causes of the abnormal proliferation in the bile ducts’ epithelial cells leading to tumors are unknown and most cases occur sporadically 

  • The total incident population of CCA in the US was estimated to be 5,567 in 2020 

  • Among the European five countries, Germany had the highest incident population of Bile Duct Cancer with 2,697 cases, followed by Italy and the United Kingdom, which had an incident population of 2,092 and 1,424 respectively in 2020. On the other hand, Spain had the lowest incident population of 249cases in2020 

  • The causes of the abnormal proliferation in the bile ducts’ epithelial cells leading to tumors are unknown and most cases occur sporadically. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural)

  • The incidence of Bile Duct Cancer has been increasing worldwide. It is usually diagnosed at advanced stages and most of the patients in these stages show a poor prognosis 

Got queries? Click here to know more about the Bile Duct Cancer Market Landscape.

Bile Duct Cancer Symptoms: 

  • You may have itchy skin, darker pee, and paler poo than usual if your skin or the whites of your eyes turn yellow (jaundice)

  • Reduction of appetite or

  • weight loss without attempting to do so

  • Feeling Unwell then general

  • Feeling Dizzy and tired

  • with a heavy head

  • A high temperature, or the sensation of being hot or shivering 

Bile Duct Cancer Market: 

The dynamics of the Bile Duct Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2018-2030. 

Melphalan/HDS (Delcath systems), Futibatinib (Taiho Oncology), Bintrafusp alfa (Merck KGaA/GSK), Derazantinib (Basilea Pharmaceutica), Larotrectinib (Loxo Oncology/Bayer), Copanlisib (Bayer), E7090 (Eisai), Futibatinib (Taiho Oncology) and many more are expected to enter in the market during the forecasted period (2022–2032). 

Learn more by requesting for sample @ Bile Duct Cancer Market Landscape  

Bile Duct Cancer Pipeline Therapies:

  • Melphalan

  • Derazantinib

  • ZW25

  • E7090

  • Futibatinib

  •  (TAS-120)

  • Bintrafusp alfa (GSK4045154; M7824) 

Bile Duct Cancer Key Companies: 

  • Delcath Systems

  • Basilea Pharmaceutica

  • Zymeworks/BeiGene

  • Bayer

  • Eisai

  • TaihoOncology

  • Merck/GlaxoSmithKline

Comments

Post a Comment

Popular posts from this blog

The Fight for Market Supremacy: OPDIVO vs. KEYTRUDA in Japan’s Cancer Treatment

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo...
Read more

Next-generation Nephrotic Syndrome Treatments: A Glimpse into the Future

Image
Nephrotic syndrome , a condition characterized by the presence of protein in the urine, swelling, low protein levels in the blood, and high cholesterol levels, poses significant challenges for patients and healthcare providers alike. While traditional approaches such as steroids and immunosuppressants have been the mainstay of treatment, emerging therapies offer new hope for individuals battling this debilitating condition. Let's delve into the landscape of nephrotic syndrome treatment, exploring both the current approaches and the promising pipeline therapies on the horizon. Traditional Approaches for Nephrotic Syndrome Treatment: Steroids and Immunosuppressants Historically, steroids and immunosuppressants have been the cornerstone of nephrotic syndrome treatment . These medications help reduce inflammation and suppress the immune system's abnormal response, thereby alleviating symptoms and slowing disease progression. However, their efficacy can vary, and long-term use may b...
Read more

FDA Approval Marks New Hope: Eli Lilly’s Donanemab for Alzheimer’s Disease

Image
  The Birth of a Breakthrough Eli Lilly’s groundbreaking drug, Donanemab, has recently received FDA approval, marking a significant milestone in Alzheimer’s disease treatment . This innovative therapy, designed to target and reduce amyloid plaques in the brain, offers new hope for patients battling this debilitating condition. Donanemab’s approval comes at a pivotal moment, as it represents a major advancement in the Alzheimer’s disease pipeline, promising improved outcomes for those affected. Navigating Regulatory Waters The journey of Donanemab through the regulatory landscape was complex, characterized by rigorous scrutiny and extensive clinical trials. Eli Lilly’s success in obtaining FDA approval highlights the drug’s potential to revolutionize Alzheimer’s disease therapies . This regulatory endorsement not only underscores the efficacy and safety of Donanemab but also sets a new standard for the evaluation of future treatments. Donanemab: Cost and Coverage As with many groun...
Read more